



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

23 MAR 2003

REC'D 04 DEC 2003

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02021622.2

**CERTIFIED COPY OF
PRIORITY DOCUMENT**

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

R C van Dijk

BEST AVAILABLE COPY



Anmeldung Nr:
Application no.: 02021622.2
Demande no:

Anmeldetag:
Date of filing: 27.09.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Roche Vitamins AG

4070 Basel
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

A gene encoding vitamin B6 phosphate phosphatase and use thereof

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C12P/

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

Roche Vitamins AG, CH-4070 Basle, Switzerland

Case 21419A gene encoding vitamin B₆ phosphate phosphatase and use thereof

The present invention relates to a novel vitamin B₆ phosphate phosphatase (VB6P phosphatase) gene, recombinant microorganisms transformed with a vector having the gene, and a polypeptide having VB6P phosphatase activity. The present invention also relates to
5 a process for preparing vitamin B₆ from VB6P using the recombinant microorganisms or the polypeptide.

"Vitamin B₆" as used in this invention includes pyridoxol (referred to as PN hereinafter), pyridoxal and pyridoxamine. Vitamin B₆ is a vitamin indispensable to human beings or other animals and used as a raw material of medicine or as feed additives.

- 10 The present invention provides recombinant microorganisms transformed with a novel VB6P phosphatase gene (namely *pdxP*), which is cloned from *Sinorhizobium meliloti*.

The present invention further provides a process for producing vitamin B₆ from VB6P by using a cell-free extract (referred to as CFE hereinafter) of the microorganisms and contacting VB6P with (i) the CFE, or (ii) enzyme preparation further purified from the above
15 CFE in the presence of Mn²⁺, Mg²⁺, Co²⁺, Sn²⁺ or Ni²⁺, and isolating the resulting vitamin B₆ from the reaction mixture.

The present invention provides an isolated deoxyribonucleic acid (DNA) encoding VB6P phosphatase and recombinant microorganisms which are capable of producing vitamin B₆ from VB6P by introducing vectors having the isolated DNA.

- 20 A VB6P phosphatase gene (*pdxP*) referred to herein means the gene encoding a VB6P phosphatase catalyzing dephosphorylation of VB6P to vitamin B₆ with high substrate specificity on pyridoxol phosphate and pyridoxal phosphate.

Hei/fm; 27.09.2002

The term "isolated", when applied to DNA, denotes that the DNA has been removed from its natural genetic environment and is thus free of other extraneous or undesired coding sequences, and is in a form suitable for use within genetically engineered protein production systems. The term "an isolated DNA" is alternatively be termed "a cloned DNA".

- 5 The term "vector" as used herein refers to a DNA molecule, linear or circular, which are generally derived from plasmid or viral DNA, or may contain elements of both. The vector may be one which is independent of chromosome replication, or one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) which it has been integrated.
- 10 The term "recombinant microorganism" refers to any microorganism transformed with a vector comprising the isolated DNA of interest. The recombinant microorganisms of the present invention express a gene encoding VB6P phosphatase for the preparation of vitamin B₆ from VB6P.

Cloning of the VB6P phosphatase gene

- 15 Purified protein of VB6P phosphatase of *S. meliloti*, e.g., is digested with a suitable protease such as trypsin and the resultant peptides are fractionated by using high pressure liquid chromatography (HPLC). Amino acid sequences of the peptides are determined by using a protein sequencer and degenerate primers are synthesized based on the amino acid sequences of the peptides. A partial fragment of VB6P phosphatase gene is obtained by
- 20 PCR with the degenerate primers. A full length of VB6P phosphate gene is obtained by screening of genomic library by using the resulting partial fragment as a probe.

An example for a suitable DNA fragment is derived from *S. meliloti*, the nucleotide sequence being illustrated as SEQ ID NO:9.

- 25 In case of *S. meliloti*, the complete genome sequence has been published (EMBL accession No. AL 591688) and the BLAST search shows that the DNA sequence of *pdxP* of *S. meliloti* represented in SEQ ID NO:9 corresponds to the region 472329-473036, complement, open reading frame SMC01730, in accession No. AL 591688 (EMBL) except for one nucleotide substitution, i.e. the nucleotide at position 163, but the function of polypeptide represented in this open reading frame SMC01730 has not been identified before.

- 30 A functional equivalent of the *S. meliloti pdxP* can be isolated from any organism, such as, but not limited to, *Mesorhizobium loti*, other bacteria, yeast, and plant.

The present invention provides DNA sequences encoding a VB6P phosphatase, as represented in SEQ ID NO:9 as well as DNA sequences which hybridize under standard conditions with the sequences represented in SEQ ID NO:9 or fragments thereof.

5 The term "DNA sequences which hybridize under standard conditions" as described herein refers to DNA obtainable by using colony hybridization, plaque hybridization or Southern hybridization wherein any DNA sequence shown in SEQ ID NO:9 is used as a probe.

10 "Standard conditions" for hybridization mean in this context the conditions which are generally used by a person skilled in the art to detect specific hybridization signals, or preferably so called stringent hybridization and non-stringent washing conditions or more preferably so called moderately stringent conditions or even more preferably so called stringent hybridization and stringent washing conditions a person skilled in the art is familiar with. A specific example thereof is DNA which can be identified by subjecting it to hybridization using the digoxigenin (referred to as DIG hereinafter) DNA Labeling and
15 detection kit (Roche Diagnostics, Tokyo, Japan) following the protocol given by the manufacturer. The hybridization solution contains 50% formamide, 5 x SSC (10 x SSC is composed of 87.65 g of NaCl and 44.1 g of sodium citrate in 1 liter), 2% blocking reagent (Roche Diagnostics, Tokyo, Japan), 0.1% N-lauroylsarcosine, and 0.3% sodium dodecyl sulfate (referred as to SDS hereinafter). Hybridization can be done overnight at 42°C and
20 then washing twice in 2 x SSC containing 0.1% SDS for 5 min at room temperature and twice in 0.1 x SSC containing 0.1 % SDS for 15 min at 50°C to 68°C. Detection can be done as indicated by manufacturer.

The present invention also includes DNA sequences which are at least 70%, preferably at least 80%, and particularly preferably more than 90% identical to the DNA sequence of
25 SEQ ID NO:9 or a fragment thereof.

Host cells and vectors

Suitable host cells for the recombinant production of vitamin B₆ from VB6P by the expression of VB6P phosphatase may be either prokaryotic or eukaryotic and will be limited only by their ability to express active enzymes. In one embodiment, the recombinant *Escherichia coli* is provided in the present invention. As a host strain, any strains belonging to the
30 genus *Escherichia* can be used, and the microorganisms belonging to the genus *Escherichia* may be isolated from natural sources, or may be purchased from culture collections. Preferably, *E. coli* JM109 (Takara, Shiga, Japan) can be used for the present invention. Suitable vectors which can be maintained in *E. coli* and used for expression of recombinant

DNA in *E. coli* include, but not limited to, pUC series plasmids, pBR322 and its derivatives such as pKK223-3.

In another embodiment, the recombinant *S. meliloti* is provided in the present invention. As a host strain, any strain belonging to the genus *Sinorhizobium* can be used, and the microorganisms belonging to the genus *Sinorhizobium* may be isolated from natural sources, or may be purchased from culture collections. Preferably, *S. meliloti* IFO 14782 (DSM 10226) can be used for the present invention. As a vector for expression of recombinant DNA in *S. meliloti*, a broad-host range vector, such as pVK100, pRK290, pLAFR1 or RSF1010, can be used. A plasmid expressing recombinant protein in *S. meliloti* can be provided by inserting a DNA fragment encoding a promoter functioning in *S. meliloti*, such as ptac, plac, ptrc, pS1 (promoter of small ribosomal subunit of *S. meliloti*), or pNm (promoter of neomycin resistant gene).

A recombinant plasmid for incorporating *pdxP* can be introduced into *S. meliloti* IFO 14782 by tri-parental mating in the following manner. *S. meliloti* as a recipient strain, *E. coli* harboring helper plasmid as a helper strain, and *E. coli* harboring donor plasmid as a donor strain are cultivated separately and mixed together. After mixed cultivation on plate, *S. meliloti* receiving a recombinant plasmid can be selected on agar plate containing appropriate antibiotics. The recombinant strain carrying the plasmids is selected by the preparation of plasmid from the colonies grown on the plates and examination by endonuclease digestion.

The procedure for constructing recombinant vectors can be performed according to standard techniques known in the art. In this invention, *pdxP* is placed in pKK223-3 under the control of ptac promoter to construct pKK*pdxP* as an expression vector in *E. coli*. In another embodiment, *pdxP* is placed in pVK100 under the control of ptac promoter to construct pVKptac*pdxP* as an expression vector in *S. meliloti*.

Polypeptides

The present invention also provides polypeptides having VB6P phosphatase activity and functional derivatives of the polypeptides. Such functional derivatives are defined on the basis of the amino acid sequences of the present invention by addition, deletion and/or substitution of one or more amino acid residues of such sequences wherein such derivatives still have the VB6P phosphatase activity. Such functional derivatives can be made either by chemical peptide synthesis known in the art or by recombinant means on the basis of the DNA sequence as disclosed herein by methods known in the state of the art. Amino acid exchanges in proteins and peptides which do not generally alter the activity of

such molecules are known in the state of the art. The most commonly occurring exchanges are: Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, Asp/Gly as well as these in reverse.

- 5 Furthermore, polypeptides according to the invention include a polypeptide according to SEQ ID NO:10, in particular those with the biological activity of VB6P phosphatase, and also those which are at least 70%, preferably at least 80%, and particularly preferably more than 90% identical to the polypeptide according to SEQ ID NO:10 and have the activity mentioned.

10 Production of vitamin B₆ from VB6P

- The recombinant microorganisms obtained in the present invention may be incubated in a medium containing an assimilable carbon source, a digestible nitrogen source, an inorganic salt, and other nutrients necessary for their growth. As a carbon source, e.g., glucose, fructose, lactose, maltose, galactose, sucrose, starch, dextrin, or glycerol may be employed. As a nitrogen source, e.g., peptone, corn steep liquor, soybean powder, yeast extract, meat extract, ammonium chloride, ammonium sulfate, ammonium nitrate, urea, or their mixture thereof may be employed. Further, for trace elements, sulfates, hydrochlorides, or phosphates of calcium, magnesium, zinc, manganese, cobalt, and iron may be employed. And, if necessary, conventional nutrient factors, a trapping agent of phosphate ion, or an antifoaming agent, such as magnesium carbonate, aluminum oxide, allophane, animal oil, vegetable oil, or mineral oil can also be added supplementary in a fermentation medium. The pH of the culture medium may be about 5.0 to about 9.0. The cultivation temperature may be in a range of from about 5°C to about 45°C. The cultivation time may be about 1 day to about 15 days. In the cultivation, aeration and agitation usually give favorable results.

- The protein having VB6P phosphatase activity may be used in the form of the culture itself which has been prepared in the above described manner, a cell-free extract (CFE) from the culture, isolated protein from the CFE, or an immobilized enzyme, to prepare vitamin B₆ from VB6P. The expression of the *pdxP* incorporated into the plasmid in suitable host cells can be analyzed by preparing CFE from the culture of recombinant microorganisms and subjecting it to SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Enzymatic production for preparing vitamin B₆ from VB6P can be achieved by bringing the enzymatically active protein into contact VB6P in an aqueous medium. The aqueous medium can be an aqueous solution, which may be buffered, if necessary. VB6P is dissolved in water and added to the aqueous medium. Production of vitamin B₆ from

VB6P, can be achieved in the aqueous medium with pH range between 5.5-9.0, preferably 7.0-8.0 and in a temperature range of from 15°C to 45°C, preferably 30°C to 40°C for 15 min to 5 hours in the presence of Mn^{2+} , Mg^{2+} , Co^{2+} , Sn^{2+} or Ni^{2+} .

After production of vitamin B₆ from VB6P, the produced vitamin B₆ may be separated from the reaction mixture and purified. For this purpose a process generally used for extracting a certain product from the reaction mixture may be applied by utilizing various properties of vitamin B₆. For example, the proteins may be denatured by heating or by adding a denaturant such as methanol or ethanol, and removed from the reaction mixture by filtration. The desired substance in the filtrate may be absorbed on active carbon, then eluted and purified further with an ion exchange resin. Alternatively, the filtrate may be applied directly to an ion exchange resin and, after the elution, the desired product may be recrystallized from mixture of alcohol and water. The amount of vitamin B₆ produced in reaction mixture can be quantified by HPLC.

The present invention will be explained more in detail by referring to the following examples.

General methods

S. meliloti IFO 14782 was used as a source of chromosomal DNA for gene cloning experiment and as a host strain for production of vitamin B₆ from VB6P by transconjugants. Derivatives of *E. coli* K-12 were also used as a host strain for molecular cloning experiments and for production of vitamin B₆ from VB6P. *E. coli* strains were cultured in LB medium (referred to as LB hereinafter) consisting of 1% Bacto Tryptone (Becton Dickinson Microbiology systems, MD, USA), 0.5% Bacto Yeast extract (Becton Dickinson Microbiology systems, MD, USA), and 0.5% NaCl, and *S. meliloti* strains were cultured in LB supplemented with 0.061% $MgSO_4 \cdot 7H_2O$ and 0.036% $CaCl_2 \cdot 2H_2O$ (referred to as LBMC hereinafter). Bacto agar (1.5%) was added to the media for preparing agar plates. Plasmid DNA was isolated from *E. coli* or *S. meliloti* with QIAGEN Midi kit (QIAGEN GmbH, Germany) or with Automatic DNA Isolation System PI-50 (Kurabo Industry Ltd., Japan). Chromosomal DNA was isolated using QIAGEN genomic-tips. Restriction enzymes, alkaline phosphatase, ligation kit, *E. coli* JM109 and HB101 competent cells (Takara Bio. Inc, Shiga, Japan), TOPO TA cloning kit (Invitrogen Japan K.K., Japan) were used according to the producer's instructions. Plasmid pKK223-3 was purchased from Amersham Biosciences Corp.. For restriction enzyme analysis, the DNA fragments were fractionated in agarose gels and isolated from the gels by means of extraction using a commercially available system with QIAEXII (QIAGEN GmbH). DNA sequence was determined with an ALF DNA sequencer (Amersham Biosciences).

Example 1: Cloning of the VB6P phosphatase gene

(1) Preparation of chromosomal DNA of *S. meliloti* IFO 14782

S. meliloti IFO 14782 was grown in LBMC at 30°C for 16 hours. The cells were harvested by centrifugation and chromosomal DNA was isolated by using QIAGEN genomic-tips.

5 (2) Acquisition of a partial fragment of VB6P phosphatase gene

To design PCR primers for cloning VB6P phosphatase gene by using degenerate PCR method, amino acid sequences of N-terminal and internal peptides were determined by using a protein sequencer, resulting in peptides Fr60 (SEQ ID NO:1), Fr64 (SEQ ID NO:2), Fr70 (SEQ ID NO:3) and N-terminal (SEQ ID NO:4).

10 The DNA, which encodes VB6P phosphatase of *S. meliloti*, was obtained by degenerate PCR method. As the forward primer, CN02 (SEQ ID NO:5) corresponding to the N-terminal amino acid sequence of VB6P phosphatase of *S. meliloti* (SEQ ID NO:4) was used. As the reverse primer, C642 (SEQ ID NO:6) corresponding to the internal amino acid sequence of VB6P phosphatase of *S. meliloti* (SEQ ID NO:2) was used.

15 PCR was performed according to the protocol of Takara Shuzo. Chromosomal DNA (0.1 µg) of *S. meliloti* IFO 14782 was used as a template, and ExTaq polymerase was used as PCR polymerase. PCR condition was as follows; 5 min at 94°C, 30 cycles of 30 seconds at 94°C, 30 seconds at 50°C, 30 seconds at 72°C, 7 min at 72°C. After the reaction, an aliquot was analyzed by agarose gel electrophoresis on 1.5% (w/v) gels and about 0.5-kb products
20 were purified by using QIAEXII and cloned into pCR2.1TOPO. DNA sequencing of three independent clones having expected inserts was performed and it was confirmed that DNA sequences of the insert fragment of the three clones were almost identical and deduced amino acid sequences obtained from the DNA sequences contained all of amino acid sequences SEQ ID NO: 1, 2, 3 and 4. One of the clones, phoC28 was used for the next
25 study. Next, PCR primers C101 (sense primer) (SEQ ID NO:7) and C102 (antisense primer) (SEQ ID NO:8) were synthesized based on the DNA sequence of insert fragment of phoC28 to obtain a partial fragment of VB6P phosphatase gene by PCR.

PCR condition was as follows; 5 min at 94°C, 30 cycles of 30 seconds at 94°C, 30 seconds at 55°C, 30 seconds at 72°C, 7 min at 72°C. Chromosomal DNA (0.1 µg) of *S. meliloti* IFO
30 14782 and ExTaq polymerase were used as a template and PCR polymerase, respectively. About 0.5-kb products were amplified by PCR as expected and the products were cloned into pCR2.1TOPO. As a result of DNA sequencing analysis, it was confirmed that several clones, which had identical sequences with phoC28, were obtained. One of the clones, pC1 was used for the next test, which had a partial fragment of VB6P phosphatase gene of
35 *S. meliloti* IFO 14782.

(3) Southern hybridization analysis of *S. meliloti* chromosomal digests

0.5-kb *EcoR* I fragments of pC1 was labeled with DIG-11-dUTP by using DIG DNA labeling kit and used as a probe for Southern hybridization analysis to determine suitable restriction enzyme to use to construct genomic library. Southern hybridization analysis was performed according to the following protocol. Chromosomal DNA (3.4 µg) was digested with restriction enzymes and subjected to agarose gel electrophoresis on 0.8% (w/v) gels. The DNA was transferred to nylon membrane in 10 x SSC by using Vacuum Blotter (Model 785 Bio-Rad). The membrane was prehybridized in hybridization buffer [50% formamide, 5 x SSC, 2% blocking reagent, 0.1% N-lauroylsarcosine, and 0.3% SDS] for 6 hours and after addition of denatured probe overnight at 42°C. The blot was washed twice in 2 x SSC containing 0.1% SDS for 5 min at room temperature and twice in 0.1 x SSC containing 0.1 % SDS for 15 min at 68°C. DNA fragments, which hybridized to the probe, were detected by using DIG detection kit. As a result, the probe hybridized to 2.3-kb *Sal* I, 3.5-kb *EcoR* I and 7.0-kb *Kpn* I DNA fragments in Southern hybridization analysis of *S. meliloti* chromosomal digests.

(4) Construction of genomic library of *S. meliloti* IFO 14782

The chromosomal DNA was partially digested with *EcoR* I subjected to agarose gel electrophoresis. The 15- to 30-kb DNA fragments were recovered from the gels and ligated into pVK100, which was digested with *EcoR* I and dephosphorylated with bacterial alkaline phosphatase. The ligation mixture was used for the *in vitro* packaging reaction and the phage particles were used to infect *E. coli* 8767 cells at the log phase of growth. The cell suspension was plated onto LB plate containing 10 µg/ml of tetracycline (referred to as Tc hereinafter). The colonies resistant to Tc were obtained and stocked as genomic library of *S. meliloti* IFO 14782.

(5) Screening of genomic library of *S. meliloti* IFO 14782

To screen colonies having the VB6P phosphatase gene of *S. meliloti* from the library prepared in Example 1-(4), the colonies grown on LB plate with 10 µg/ml of Tc were transferred to the nylon transfer membrane (Hybond™-N⁺ Amersham Pharmacia Biotech) and subjected to colony hybridization with the probe prepared in Example 1-(3). Among 3000 clones of the genomic library of *S. meliloti* IFO 14782, seven positive colonies were obtained. Plasmids were prepared by using QIAGEN-midi tip from the positive colonies, and digested with restriction enzymes, *EcoR* I and *Sal* I. The digested plasmids were subjected to agarose gel electrophoresis on 1.0% (w/v) gels and Southern hybridization analysis was performed as described in Example 1-(3) and it was confirmed that the probe was hybridized to 2.3-kb of *Sal* I and 3.5-kb *EcoR* I fragments of digested plasmids. One of

the plasmids from positive colonies, which have about 24-kb *EcoR* I fragment, was named pVEC1.

(6) Sequencing of VB6P phosphatase gene

2.3-kb *Sal* I and 3.5-kb *EcoR* I fragments of pVEC1 were ligated into pUC19 and obtained plasmids were named pUCEC1 and pUCEC19, respectively. The nucleotide sequence of the insert fragment of pUCEC1 and pUCEC19 was determined with an ALF DNA sequencer. As a result of the DNA sequencing, 708-bp sequence encoded ORF consisting of 235 amino acids, which contains all amino acid sequences SEQ ID NO:1, 2, 3 and 4, was observed. This result showed that the 708-bp sequence as shown in SEQ ID NO:9, corresponded to VB6P phosphatase gene, and this gene was named *pdxP*. The restriction map of chromosomal DNA around *pdxP* is shown in Fig. 1.

Example 2: Expression of *pdxP* and production of vitamin B₆ from VB6P

(1) Expression of *pdxP* in *E. coli*

To express the *pdxP* gene under the control of the tac promoter in *E. coli*, the plasmid pKKpdxP was constructed. The *pdxP* gene was amplified from 100 ng of chromosomal DNA of *S. meliloti* IFO 14782 by advantage-HF PCR kit (Clontech, USA) using 10-pmol of the primers, Primer P101 (SEQ ID NO: 11) and Primer P102 (SEQ ID NO: 12).

The reaction conditions were as follows: after holding 15 seconds at 94°C, 30 cycles of 15 seconds at 94°C, 4 min at 68°C. The reaction mixture was subjected to agarose gel electrophoresis and a 0.86-kb DNA fragment was recovered from the gels with QIAEXII. The obtained 0.86-kb fragment was cloned in pCRII-TOPO vector by TOPO TA cloning kit, and the obtained 5 independent candidates were examined for DNA sequence of insert fragment. As a result, one of the candidates, TOPOpdxP105, which had exact insert sequence, was used for further study.

0.86-kb *Sma* I fragment from TOPOpdxP105 was ligated into *Sma* I site of pKK223-3 in an orientation that allowed transcription of *pdxP* from tac promoter and resulting plasmid was named pKKpdxP (Fig. 2).

Then two independent clones JM109 having pKKpdxP (namely, JM109/pKKpdxP-1 and JM109/pKKpdxP-7) were grown in LB with 100 µg/ml ampicillin (Amp) and 1 mg/ml pyridoxamine. After 1.5-hour cultivation, the expression of *pdxP* was induced by adding 1 mM isopropyl-β-D-thiogalactopyranose (IPTG). After cultivation for another 4.5 hours, the cells were harvested and suspended in 20 mM Tris-HCl, pH 7.5, buffer containing 15% sucrose, 1 mM dithiothreitol (DTT), 1 mM MnCl₂, 1 mM MgCl₂, and 0.1 mM phenylmethylsulfonyl fluoride (PMSF). The cell suspension was subjected to a French press at a pressure of 800 kg/cm² and the resultant lysate was centrifuged at 35,000 x g for 60 min at

4°C to remove cell debris. The supernatant was used as the CFE after dialysis with the same buffer. To confirm the expression of PdxP, CFE was subjected to SDS-PAGE on 12.5 % (w/v) gels and stained with Coomassie Brilliant Blue (Rapid Stain CBB Kit, nacalai tesque Japan). Overproduction of polypeptide with an expected molecular size (29.0 kDa) was detected in *E. coli* JM109/pKKpdxP-1 but not in *E. coli* JM109/pKKpdxP-7. Then the CFE of *E. coli* JM109/pKKpdxP-1 was used for further study.

(2) Production of vitamin B₆ from VB6P in CFE of recombinant *E. coli*

Production of vitamin B₆ from VB6P was done by using the CFE prepared in Example 2-

(1). The reaction mixture contained 50 mM Tris-HCl buffer, pH 7.5, 2 mM pyridoxol 5'-phosphate (PNP), 1 mM MnCl₂ and CFE (0.5 mg protein) in 125 µl. The reaction was done at 37°C for 15 min and the amount of PN was quantified by HPLC by the internal standard method with 4'-deoxypyridoxol as described below. To prepare the samples for HPLC, 200 µl of 100 mg/l of 4'-deoxypyridoxol as an internal substance, 50 µl of 60% perchloric acid, and 950 µl of deionized water was added to 50 µl of the standard solution of pyridoxol or the reaction mixture, and then the mixture was put on the ice for 10 min. Then the mixture was centrifuged at 15,000 rpm and the supernatant was put on the following column. The analytical conditions were as follows: column: Capcell pak C18 SG120 (4.6 × 250 mm) (Shiseido Co., Ltd., Tokyo, Japan); mobile phase: 0.1 M sodium perchlorate, 0.1 M potassium phosphate, and 2% acetonitrile (pH 3.5); column temperature: 30°C; flow rate, 1.0 ml/min; and detector: ultraviolet (at 292 nm). The result is shown in Table 5. The concentration of formed PN in the reaction mixture containing CFE of JM109/pKKpdxP was 0.50 mM and it was 1.4 times higher than that of JM109/pKK223-3 (0.37 mM).

Table 5 Amount of formed PN in CFE of JM109/pKKpdxP

CFE	Formed PN	
	(mM)	(Ratio)
JM109/pKK223-3 (vector)	0.37	1
JM109/pKKpdxP	0.50	1.4
minus CFE	ND	ND

ND: Not detectable

(3) Expression of *pdxP* in *S. meliloti*

Mobilizable cosmid pVK100 was digested with *Bgl* II, then about 21.3-kb fragments were recovered. After the fragments were treated with bacterial alkaline phosphatase, 1.1-kb

*Bam*H I fragments from pKKpdxP were ligated into the *Bgl* II digested and dephosphorylated fragment to give a plasmid pVKPtacpdxP (Fig. 3). Then *S. meliloti* IFO 14782 having pVKPtacpdxP was obtained by tri-parental conjugation, and the cells were grown in the seed medium containing 1% glucose, 0.5% polypeptone, 0.2% Bacto Yeast extract, 0.1% KH_2PO_4 , 0.05% $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.001% $\text{MnSO}_4 \cdot 5\text{H}_2\text{O}$, and 0.001% $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, and seed culture was transferred into glucose-polypeptone medium containing 4% glucose, 2% polypeptone, 0.2% Bacto Yeast extract, 0.05% $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.05% $\text{MnSO}_4 \cdot 5\text{H}_2\text{O}$, and 0.001% $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, and cultivated at 30°C for 3 days. The cells were harvested by centrifugation and washed with saline and suspended with 20 mM Tris-HCl, pH 7.5, buffer containing 15% sucrose, 1 mM DTT, 1 mM MnCl_2 , 1 mM MgCl_2 , and 0.1 mM PMSF. The cell suspension was subjected to a French press at a pressure of 800 kg/cm² and the resultant lysate was centrifuged at 35,000 ×g for 60 minutes at 4°C to remove cell debris. The supernatant was used as CFE after dialysis with the same buffer.

(4) Production of vitamin B₆ from VB6P by CFE of recombinant *S. meliloti*

- 15 Production of vitamin B₆ from VB6P was examined by using the CFE prepared in Example 2-(3). The reaction mixture contained 50 mM Tris-HCl buffer, pH 7.5, 2 mM PNP, 1 mM MnCl_2 , and CFE (0.4 mg protein) in 125 μl . The reaction was done at 37°C for 30 min and the amount of PN was quantified by HPLC as shown in Example 2-(2). The result is shown in Table 6. The concentration of formed PN in reaction mixture containing CFE of
- 20 *S. meliloti* IFO 14782/pVKPtacpdxP was 1.66 mM and it was 4 times higher than that of *S. meliloti* IFO 14782 (0.41 mM).

Table 6: Amount of formed PN in CFE of *S. meliloti* IFO 14782/pVKPtacpdxP

CFE	Formed PN	
	(mM)	(Ratio)
<i>S. meliloti</i> IFO 14782	0.41	1
<i>S. meliloti</i> IFO 14782/pVKPtacpdxP	1.66	4.0
minus CFE	ND	ND

ND: Not detectable

- 12 -

Claims

1. An isolated DNA encoding vitamin B₆ phosphate phosphatase selected from the group consisting of:
 - (a) a DNA sequence represented in SEQ ID NO:9;
 - 5 (b) a DNA sequence which encodes a polypeptide having vitamin B₆ phosphate phosphatase activity and hybridizes under standard conditions to the DNA sequence defined in (a) or a fragment of thereof;
 - (c) a DNA sequence which encodes a polypeptide having vitamin B₆ phosphate phosphatase activity, wherein said polypeptide is at least 70 % identical to the amino acid sequence represented in SEQ ID NO:10;
 - 10 (d) a DNA sequence which encodes a polypeptide having vitamin B₆ phosphate phosphatase activity and is at least 70 % identical to the DNA sequence represented in SEQ ID NO:9;
 - (e) a degenerate DNA sequence of any one of (a) to (c).
- 15 2. A vector or plasmid comprising the isolated DNA of claim 1.
3. A polypeptide encoded by the isolated DNA of claim 1.
4. A recombinant microorganism of the genus *Sinorhizobium* or *Escherichia*, capable of producing vitamin B₆ from vitamin B₆ phosphate, wherein said microorganism is transformed with the DNA of claim 1 or the vector or plasmid of claim 2.
- 20 5. The microorganism of claim 4, wherein said microorganism is *Sinorhizobium meliloti* IFO 14782 having pVKPtacpdxP (*S. meliloti* IFO 14782/pVKPtacpdxP).
6. The microorganism of claim 4, wherein said microorganism is *Escherichia coli* JM109 having pKKpdxP (*E. coli* JM109/pKKpdxP).
7. A process for preparing a cell-free extract having vitamin B₆ phosphate phosphatase activity, which comprises cultivating the microorganism according to claim 4 wherein the
25 microorganism is cultivated under conditions in a medium containing an assimilable carbon source, a digestible nitrogen source, inorganic salts, and other nutrients necessary for the growth of the microorganism at a pH value of about 5.0 to about 9.0, at a temperature of about 5°C to about 45°C, and for 1 day to about 15 days under aerobic conditions, and disrupting cells of the microorganism.
30
8. The process for producing vitamin B₆ from vitamin B₆ phosphate which comprises contacting vitamin B₆ phosphate with the cell-free extract of microorganism according to

- 13 -

claim 4 in a reaction mixture, and recovering the resulting vitamin B₆ from the reaction mixture.

9. The process according to claims 7 or 8, wherein said microorganism is *Sinorhizobium meliloti* IFO 14782 having pVKPtacpdxP (*S. meliloti* IFO 14782/pVKPtacpdxP).
- 5 10. The process according to claims 7 or 8, wherein said microorganism is *Escherichia coli* JM109 having pKKpdxP (*E. coli* JM109/pKKpdxP).

- 14 -

SEQUENCE LISTING

<110> Roche Vitamins AG
 <120> A gene encoding vitamin B6 phosphate phosphatase and use thereof
 <130> NDR5234
 5 <160> 12
 <170> PatentIn version 3.1

 <210> 1
 <211> 20
 10 <212> PRT
 <213> Sinorhizobium meliloti

 <400> 1

 15 Ala His Ala Ile Asp Tyr Ser Val Val Pro Ala Asp Pro Ala Leu Gly
 1 5 10 15

 Glu Ala Ile Lys
 20
 20

 <210> 2
 <211> 14
 <212> PRT
 25 <213> Sinorhizobium meliloti

 <400> 2

 Ile Asp Thr Ala Asn Ala Val Met Phe Glu Asp Leu Pro Arg
 30 1 5 10

 <210> 3
 <211> 23
 35 <212> PRT
 <213> Sinorhizobium meliloti

 <400> 3

 40 Asp His Gly Thr Thr Leu Gln Gly Leu Met Leu His His Gly Ile Asp
 1 5 10 15
 Pro Asn Asp Phe Leu Glu Arg
 20

- 15 -

<210> 4
 <211> 10
 <212> PRT
 5 <213> Sinorhizobium meliloti
 <400> 4

10 1 Met Lys Lys Leu Asp Arg Met Pro Thr His
 5 10

15 <210> 5
 <211> 21
 <212> DNA
 <213> Artificial
 <220>
 <221> misc_feature
 <222> (18)..(18)
 20 <223> n is inosine
 <220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is inosine
 25 <400> 5
 atgaaraary tngaymgnat g

21

30 <210> 6
 <211> 20
 <212> DNA
 <213> Artificial
 <220>
 35 <221> misc_feature
 <222> (12)..(12)
 <223>
 <220>
 <221> misc_feature
 40 <222> (15)..(15)
 <223> n is a, g, c or t
 <220>
 <221> misc_feature
 <222> (12)..(12)

-16-

<223> n, is a, g, c or t
 <400> 6
 tcytcaaca tncangcrtt 20
 5
 <210> 7
 <211> 21
 <212> DNA
 10 <213> Artificial
 <400> 7
 gccgaattcg cccatgtcac c 21
 15
 <210> 8
 <211> 21
 <212> DNA
 <213> Artificial
 20
 <400> 8
 cgccgtgtcg atgagggtgaa g 21
 25
 <210> 9
 <211> 708
 <212> DNA
 <213> Sinorhizobium meliloti
 <220>
 30 <221> CDS
 <222> (1) .. (708)
 <223>
 <400> 9
 35 atg aag aag ctc gac cgc atg ccg acc cac gcc gaa ttc gcc cat gtc 48
 Met Lys Lys Leu Asp Arg Met Pro Thr His Ala Glu Phe Ala His Val
 1 5 10 15
 acc gac tgg gtc ttc gac ctc gac aac acg ctc tat ccg cat cac gtc 96
 40 Thr Asp Trp Val Phe Asp Leu Asp Asn Thr Leu Tyr Pro His His Val
 20 25 30
 aat ctg ttc tca cag atc gac cgc aac atg acg gcc tat gtc gcc gaa 144
 Asn Leu Phe Ser Gln Ile Asp Arg Asn Met Thr Ala Tyr Val Ala Glu

- 17 -

	35	40	45	
	ctc ctg tgc ctg gag cct gcg gag gcg aag aag ctg cag aag gaa tac			192
5	Leu Leu Ser Leu Glu Pro Ala Glu Ala Lys Lys Leu Gln Lys Glu Tyr			
	50	55	60	
	tac cgc gac cac ggc acc acg ctc cag ggc ctg atg ctt cat cac ggc			240
	Tyr Arg Asp His Gly Thr Thr Leu Gln Gly Leu Met Leu His His Gly			
	65	70	75	80
10	atc gat ccc aat gat ttc ctc gaa aga gcc cac gcc atc gac tat agc			288
	Ile Asp Pro Asn Asp Phe Leu Glu Arg Ala His Ala Ile Asp Tyr Ser			
		85	90	95
15	gtg gtg ccg gcc gat ccg gcg ctc ggc gag gcg atc aag gcg ctg ccc			336
	Val Val Pro Ala Asp Pro Ala Leu Gly Glu Ala Ile Lys Ala Leu Pro			
		100	105	110
	gga cgc aag ttc atc ttc acc aac ggc agc gtc gcc cat gcg gag atg			384
20	Gly Arg Lys Phe Ile Phe Thr Asn Gly Ser Val Ala His Ala Glu Met			
		115	120	125
	acc gcg cgg gcg ctc ggc att ctc gag cat ttc aac gac atc ttc gac			432
	Thr Ala Arg Ala Leu Gly Ile Leu Glu His Phe Asn Asp Ile Phe Asp			
25		130	135	140
	atc gtc gcc gcc ggc ttc ata ccg aag ccc gcc ggc gac acc tac gac			480
	Ile Val Ala Ala Gly Phe Ile Pro Lys Pro Ala Gly Asp Thr Tyr Asp			
	145	150	155	160
30	aag ttc atg ggc ctt cac cgc atc gac acg gcg aat gag ctg atg ttc			528
	Lys Phe Met Gly Leu His Arg Ile Asp Thr Ala Asn Ala Val Met Phe			
		165	170	175
35	gag gat ctg ccg cgc aac ctg gtc gtc cct aag gcg ctc ggc atg aag			576
	Glu Asp Leu Pro Arg Asn Leu Val Val Pro Lys Ala Leu Gly Met Lys			
		180	185	190
	acg gtg ctg ctc gtg ccg cgc aat ctc gaa tac gag ttc gcc gag gcc			624
	Thr Val Leu Leu Val Pro Arg Asn Leu Glu Tyr Glu Phe Ala Glu Ala			
40		195	200	205
	tgg gaa acg tgc agc gac gcg gac gat cag atc gac tac ctc acg gaa			672
	Trp Glu Thr Ser Ser Asp Ala Asp Asp Gln Ile Asp Tyr Val Thr Glu			
	210	215	220	

-18-

708

gac ctg gcg ggt ttc ctg cgc agt gtg att gtt tag
 Asp Leu Ala Gly Phe Leu Arg Ser Val Ile Val
 225 230 235
 5
 <210> 10
 <211> 235
 <212> PRT
 10 <213> Sinorhizobium meliloti
 <400> 10
 Met Lys Lys Leu Asp Arg Met Pro Thr His Ala Glu Phe Ala His Val
 15 1 5 10 15
 Thr Asp Trp Val Phe Asp Leu Asp Asn Thr Leu Tyr Pro His His Val
 20 20 25 30
 Asn Leu Phe Ser Gln Ile Asp Arg Asn Met Thr Ala Tyr Val Ala Glu
 35 40 45
 Leu Leu Ser Leu Glu Pro Ala Glu Ala Lys Lys Leu Gln Lys Glu Tyr
 50 55 60
 25
 Tyr Arg Asp His Gly Thr Thr Leu Gln Gly Leu Met Leu His His Gly
 65 70 75 80
 Ile Asp Pro Asn Asp Phe Leu Glu Arg Ala His Ala Ile Asp Tyr Ser
 30 85 90 95
 Val Val Pro Ala Asp Pro Ala Leu Gly Glu Ala Ile Lys Ala Leu Pro
 100 105 110
 35 Gly Arg Lys Phe Ile Phe Thr Asn Gly Ser Val Ala His Ala Glu Met
 115 120 125
 Thr Ala Arg Ala Leu Gly Ile Leu Glu His Phe Asn Asp Ile Phe Asp
 130 135 140
 40 Ile Val Ala Ala Gly Phe Ile Pro Lys Pro Ala Gly Asp Thr Tyr Asp
 145 150 155 160
 Lys Phe Met Gly Leu His Arg Ile Asp Thr Ala Asn Ala Val Met Phe
 165 170 175

- 19 -

Glu Asp Leu Pro Arg Asn Leu Val Val Pro Lys Ala Leu Gly Met Lys
 180 185 190

5 Thr Val Leu Leu Val Pro Arg Asn Leu Glu Tyr Glu Phe Ala Glu Ala
 195 200 205

Trp Glu Thr Ser Ser Asp Ala Asp Asp Gln Ile Asp Tyr Val Thr Glu
 210 215 220

10

Asp Leu Ala Gly Phe Leu Arg Ser Val Ile Val
 225 230 235

<210> 11

15 <211> 32

<212> DNA

<213> Artificial

<400> 11

20 gaagcttccc gggccgtgtc ataaaccgc cc

32

<210> 12

<211> 32

<212> DNA

25 <213> Artificial

<400> 12

caagcttccc gggatcatcg ccgggtttta cg

32

Fig. 1 -





Fig. 2

Sma I cassette of *pdxP* by HF PCR



pKK223-3 (4.6 Kb)

↓ *Sma* I digestion
 ↓ BAP

Ligation




Fig. 4


Vector pVK100

Bgl II digestion
/ 21.3 Kb


BAP

pKK-pdxP

*Bam*HI digestion
/ 1.1Kb




Ligation



PCT Application

EP0310575



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.